Baker Legal Team launches Dupixent lymphoma claims site

Baker Legal Team has launched ctcllawyer.com for patients diagnosed with cutaneous T-cell lymphoma or other T-cell lymphoma after using Dupixent. The move comes as federal judges consolidate Dupixent product liability cases and plaintiffs allege the drug’s makers failed to warn about a possible lymphoma risk. Why it matters: - The new site gives patients a focused entry point for information about possible Dupixent-related lymphoma claims. - The launch comes as Dupixent litigation moves into a federal multidistrict case, which can speed pretrial proceedings and shape the pace of claims. - Patients diagnosed with CTCL, mycosis fungoides, Sézary syndrome or other T-cell lymphomas may have a path to a free case review. What happened: - Baker Legal Team launched ctcllawyer.com on June 16, 2026, in Boca Raton, Florida. - The website is aimed at patients diagnosed with cutaneous T-cell lymphoma or other forms of T-cell lymphoma after using Dupixent, also known as dupilumab. - The launch followed the Judicial Panel on Multidistrict Litigation’s June 4, 2026 decision to create MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation. - The MDL centralized federal Dupixent cases before Judge Zahid N. Quraishi in the U.S. District Court for the District of New Jersey. The details: - The lawsuits allege Regeneron Pharmaceuticals and Sanofi-Aventis U.S., the makers of Dupixent, failed to warn patients and physicians about a possible link between the drug and T-cell lymphoma. - Dupixent is a biologic used to treat eczema, asthma and other inflammatory conditions. - Peer-reviewed studies have reported elevated rates of CTCL among patients treated with Dupixent. - As of June 2026, the FDA-approved Dupixent label does not include a specific warning about CTCL or lymphoma. - The FDA has identified CTCL as a potential safety signal connected to the medication. - The website includes plain-language information about the litigation, the diagnoses involved and warning signs of CTCL. - The site also offers a free and confidential case review for patients who may qualify. - Baker Legal Team says it handles these claims on a contingency basis, so clients pay no attorney fees unless they recover compensation. - The firm urges patients not to stop taking prescribed medication without first consulting a physician. - Patients who used Dupixent and were later diagnosed with CTCL, mycosis fungoides, Sézary syndrome or another T-cell lymphoma can learn more at ctcllawyer.com . Between the lines: - The website launch is a legal-marketing move timed to a newly consolidated federal case, signaling that Dupixent-related claims are entering a more organized phase. - The absence of a specific lymphoma warning on the label may become a central issue in the litigation. - Robert Baker framed the lawsuits as a duty-to-warn case, saying patients and doctors deserve to know about any information suggesting a cancer link. What’s next: - More Dupixent cases are likely to flow into the MDL as patients and lawyers evaluate diagnoses and treatment histories. - The federal court process will now handle shared discovery and pretrial issues for the consolidated cases. - Patients seeking to evaluate a potential claim can use the new site for a confidential review and additional information. The bottom line: - Baker Legal Team is positioning itself for the next phase of Dupixent lymphoma litigation by pairing a new patient resource with a fast-growing federal MDL.